Internal Medicine · Clinical Calculator · Pulmonary Embolism

PESI 30-day mortality risk after acute PE

The Pulmonary Embolism Severity Index (PESI) is a points-weighted 11-variable score that stratifies 30-day all-cause mortality after confirmed pulmonary embolism into five classes. Class I (≤ 65 points) and Class II (66–85 points) identify low-risk patients who may be candidates for outpatient management or early discharge; Class IV–V flag patients who need closer monitoring and may benefit from advanced reperfusion therapy.

Published: References: 3 Read time:

← All calculators & tools  ·  Wells' criteria for PE →

Instructions
  1. Only apply PESI to patients with acute, objectively confirmed pulmonary embolism (CT pulmonary angiogram or V/Q scan).
  2. Enter the patient's age in years — age in years is added directly to the score as raw points.
  3. Toggle each of the 10 clinical variables ON if present at the time of PE diagnosis; leave OFF if absent.
  4. The total score and its PESI class (I–V) appear automatically, along with the predicted 30-day all-cause mortality band.
  5. Use the class with the clinical context (right-ventricular dysfunction, cardiac biomarkers, comorbidity) to decide between inpatient vs. outpatient management, intensity of monitoring, and whether advanced reperfusion is appropriate.

All computation runs in your browser; no values are stored or transmitted.

When to Use

Apply PESI as part of the risk stratification that follows a confirmed diagnosis of acute pulmonary embolism. It is endorsed by the 2019 European Society of Cardiology (ESC) guidelines for identifying the subset of patients who are low risk for 30-day mortality and therefore candidates for early discharge or outpatient treatment with a direct oral anticoagulant (DOAC), as demonstrated in the HESTIA and HOT-PE trials.

✅

Appropriate population

Adult patients with acute, objectively confirmed pulmonary embolism. PESI's derivation and validation cohorts spanned the full clinical spectrum from ambulatory outpatients to critically ill inpatients; the same points-weighted score applies across this range.

⚠️

When NOT to rely on PESI alone

PESI is a clinical prognostic score — it does not incorporate right-ventricular (RV) dysfunction on echocardiography or CT, cardiac troponin, or B-type natriuretic peptide (BNP / NT-proBNP). In the ESC pathway, a low PESI (or simplified PESI = 0) still requires absence of RV dysfunction and normal cardiac biomarkers before a patient is classified as truly low risk and considered for outpatient management. PESI should not be used in pregnant patients, patients with hemodynamic instability (massive PE — they are high-risk by definition), or in situations where the limited-case variables are confounded by comorbidity.

Pearls & Pitfalls
💡

Age carries the most weight

Age is entered as raw years, so a 75-year-old starts at 75 points before any other factor is considered. The practical consequence: elderly patients almost never reach Class I even when every other variable is negative. If a very low risk group is the goal (e.g. for outpatient discharge), use the simplified PESI, which uses an age threshold (> 80) instead of raw age and performs comparably for the binary low/high decision.

🔬

Classes and mortality bands

Class I (≤ 65): very low, 0.0–1.6% 30-day mortality. Class II (66–85): low, 1.7–3.5%. Class III (86–105): intermediate, 3.2–7.1%. Class IV (106–125): high, 4.0–11.4%. Class V (> 125): very high, 10.0–24.5%. These bands come from the original derivation and prospective external validation cohorts (Aujesky 2005; Donzé 2008).

🚫

Pitfalls

(1) PESI predicts all-cause mortality, not PE-specific mortality — in elderly multimorbid patients, a high class may be driven by non-PE causes of death. (2) The "history of cancer" variable is any active or recent cancer, not remote history in remission. (3) "History of heart failure" and "history of chronic lung disease" are each single points of 10, but a patient with combined cardiopulmonary disease still only scores 20 for both; the simplified PESI combines them into a single item. (4) The sat < 90% variable counts whether or not the patient is on supplemental oxygen — unlike PERC, this is not a room-air-only criterion.

Why Use It

Mortality after pulmonary embolism varies more than 20-fold between patients — from under 2% in young, hemodynamically stable outpatients to above 20% in elderly patients with hypotension, hypoxemia, or altered mental status. Clinical gestalt systematically overestimates risk and defaults to hospital admission even when the patient is at very low risk. PESI operationalizes 11 easily-ascertained variables into a validated, reproducible 30-day mortality estimate, and the 2019 ESC guidelines put PESI (or simplified PESI) at the center of the PE risk-stratification pathway. In practice it guides four decisions: inpatient vs. outpatient management, intensity of monitoring, the decision to pursue advanced reperfusion for intermediate-high-risk patients, and the choice between parenteral anticoagulation and a DOAC from day one.

PESI — Pulmonary Embolism Severity Index

Enter age in years, then toggle each of the 10 other variables ON if present. The total score and PESI class update automatically.

Required. Entered in raw years; each year adds 1 to the score.
e.g. 68-year-old man
e.g. metastatic colon cancer on treatment
e.g. HFrEF, ejection fraction 35%
e.g. COPD stage 2 on inhaled therapy
e.g. heart rate 118 bpm
e.g. 92/60 mmHg
e.g. 32 breaths per minute
e.g. tympanic 35.6 °C
e.g. GCS 13 or disoriented to place
e.g. SpO₂ 86% (room air or supplemental)
—
PESI score
enter age
—
PESI class
I–V
—
30-day mortality
all-cause

⚕ Aujesky D et al. Am J Respir Crit Care Med. 2005;172(8):1041–1046. PESI predicts 30-day all-cause mortality after confirmed acute pulmonary embolism. The 2019 ESC guidelines pair PESI (or sPESI) with assessment of right-ventricular (RV) dysfunction and cardiac biomarkers (troponin, BNP) before classifying a patient as truly low risk and considering outpatient management. For licensed clinicians; not a substitute for individualized clinical judgment.

Next Steps

Use the PESI class to shape disposition and intensity of monitoring.

  • Class I (≤ 65) and Class II (66–85): very low and low risk. Consider early discharge or fully outpatient management with a direct oral anticoagulant (DOAC) if there is no right-ventricular dysfunction on echocardiography or computed tomography pulmonary angiogram (CTPA), cardiac biomarkers (troponin, BNP) are normal, no significant comorbidity, and reliable social support (per HESTIA / HOT-PE criteria and ESC 2019).
  • Class III (86–105): intermediate risk. Standard inpatient anticoagulation with monitoring on a general ward. Re-stratify with imaging and biomarkers.
  • Class IV (106–125) and Class V (> 125): high and very high risk. Higher-level monitoring (step-down or intensive care unit depending on hemodynamics). If hemodynamically unstable (massive PE) or in the intermediate-high ESC category with RV dysfunction plus elevated troponin, consider systemic thrombolysis, catheter-directed therapy, or surgical embolectomy.
  • If the goal is a simple binary low-vs-high decision for outpatient management, consider the simplified PESI (sPESI) — six yes/no items, with the same discharge implications when the score is 0.
Evidence & References

The 11 PESI Variables

VariablePoints
Age (years)+1 per year (raw value)
Male sex+10
History of cancer+30
History of heart failure+10
History of chronic lung disease+10
Pulse ≥ 110 bpm+20
Systolic blood pressure < 100 mmHg+30
Respiratory rate ≥ 30 / min+20
Temperature < 36 °C+20
Altered mental status (confusion, lethargy, disorientation, coma)+60
Arterial O₂ saturation < 90% (room air or supplemental)+20

PESI Classes and 30-Day Mortality

ClassScoreRisk30-day all-cause mortality
Class I≤ 65Very low0.0 – 1.6%
Class II66 – 85Low1.7 – 3.5%
Class III86 – 105Intermediate3.2 – 7.1%
Class IV106 – 125High4.0 – 11.4%
Class V> 125Very high10.0 – 24.5%

Aujesky and colleagues derived PESI from 10,354 patients across 186 U.S. hospitals and validated it in an external cohort of 221 patients from 29 Swiss and French hospitals; Donzé and colleagues independently prospectively validated the five-class structure in six European centers.

Important: This calculator is an educational aid for licensed clinicians and does not replace individualized clinical assessment. PESI estimates 30-day all-cause mortality in patients with confirmed acute pulmonary embolism; it does not incorporate right-ventricular dysfunction on imaging or cardiac biomarkers, both of which are part of the 2019 ESC risk-stratification pathway. Always integrate the result with echocardiography or CTPA findings, troponin and BNP, comorbidities, patient preferences, and current institutional protocols before deciding on disposition, monitoring, or reperfusion therapy.
References 3 sources
  1. Aujesky, D., Obrosky, D. S., Stone, R. A., Auble, T. E., Perrier, A., Cornuz, J., Roy, P.-M., & Fine, M. J. (2005). Derivation and validation of a prognostic model for pulmonary embolism. American Journal of Respiratory and Critical Care Medicine, 172(8), 1041–1046. https://doi.org/10.1164/rccm.200506-862OC
  2. Donzé, J., Le Gal, G., Fine, M. J., Roy, P.-M., Sanchez, O., Verschuren, F., Cornuz, J., Meyer, G., Perrier, A., Righini, M., & Aujesky, D. (2008). Prospective validation of the Pulmonary Embolism Severity Index. A clinical prognostic model for pulmonary embolism. Thrombosis and Haemostasis, 100(5), 943–948. https://doi.org/10.1160/TH08-05-0285
  3. Konstantinides, S. V., Meyer, G., Becattini, C., Bueno, H., Geersing, G.-J., Harjola, V.-P., Huisman, M. V., Humbert, M., Jennings, C. S., Jiménez, D., Kucher, N., Lang, I. M., Lankeit, M., Lorusso, R., Mazzolai, L., Meneveau, N., Ní Áinle, F., Prandoni, P., Pruszczyk, P., Righini, M., Torbicki, A., Van Belle, E., & Zamorano, J. L. (2020). 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). European Heart Journal, 41(4), 543–603. https://doi.org/10.1093/eurheartj/ehz405
Dr. W Rivero, MD

W Rivero, MD, FPCP, DPSN

Specialist in Internal Medicine, Nephrology, and Clinical Nutrition. Practicing integrative and evidence-based nephrology across Quezon City, Pampanga, and Bulacan.

· Book an Appointment →

QR code — scan to save Dr. Rivero's contact info

Scan and save

All Calculators Related Guides